Given that hypoxia is a common feature of tumor microenvironment that drives tumor progression and that metabolic reprogramming is considered a new target for cancer therapy [25–27], our study may help to better understand the oncogenic potential of LOXL2 in the hypoxic microenvironment and metabolic reprogramming. This evidence concerns the gene LOXL2 and cancer.